Hair Thinning: When to See a Doctor

Why You Are Losing Hair: The Main Causes

Hair thinning has a defined biological cause in the vast majority of patients. The most common diagnoses are androgenetic alopecia, telogen effluvium, thyroid dysfunction, nutritional deficiency, and alopecia areata. Identifying the correct diagnosis determines whether the condition is reversible, and how fast treatment should start.

Androgenetic Alopecia (Genetic Hair Loss)

Androgenetic alopecia (AGA) is the single most common cause of progressive hair thinning in both sexes. In men it produces a receding hairline and crown thinning following the Hamilton-Norwood classification. In women it produces diffuse thinning over the crown while the frontal hairline is usually preserved, graded by the Ludwig scale.

The mechanism involves dihydrotestosterone (DHT) binding to androgen receptors in genetically susceptible follicles, shortening the anagen (growth) phase over successive cycles until the follicle miniaturizes. A 2017 genome-wide association study published in PLOS Genetics identified more than 250 independent genetic loci associated with male-pattern baldness, confirming the polygenic nature of the condition (1).

AGA affects approximately 50% of men by age 50 and up to 40% of women by age 70 (2). The condition is chronic and progressive without intervention.

Telogen Effluvium

Telogen effluvium (TE) is diffuse, often dramatic shedding that follows a systemic stressor by roughly 2 to 3 months. Common triggers include childbirth, major surgery, severe illness (including COVID-19), rapid weight loss exceeding 15 pounds in 3 months, and prolonged psychological stress.

During TE, a disproportionate number of follicles shift prematurely from the anagen phase into the telogen (resting) phase, then shed synchronously. A prospective review in the Journal of the American Academy of Dermatology described TE as the second most common cause of hair loss seen in outpatient dermatology practice (3). Acute TE typically resolves within 6 to 9 months once the triggering factor is corrected. Chronic TE, defined as lasting beyond 6 months, warrants further evaluation for an ongoing systemic cause.

Thyroid Disease and Hormonal Causes

Both hypothyroidism and hyperthyroidism can cause diffuse hair thinning. Thyroid hormone receptors are present in the hair follicle bulb, and disrupted signaling prolongs the telogen phase. The American Thyroid Association recommends a serum TSH as the first-line test for suspected thyroid dysfunction (4).

Polycystic ovary syndrome (PCOS), elevated androgens, and postpartum estrogen withdrawal are additional hormonal drivers. Prolactin elevation and adrenal disorders can also suppress follicular cycling.

Nutritional Deficiencies

Iron deficiency is the nutritional deficiency most strongly linked to hair shedding, even before frank anemia develops. A serum ferritin below 30 ng/mL is frequently cited as a threshold associated with TE in women, though the relationship remains dose-dependent (5). Zinc deficiency, biotin deficiency (rare outside of parenteral nutrition or certain medications), and very low protein intake are additional contributors.

Crash diets and bariatric surgery carry a well-documented risk: a 2021 systematic review in Obesity Surgery found that 57% of patients reported notable hair shedding in the 3 to 6 months following Roux-en-Y gastric bypass, driven largely by combined caloric restriction and micronutrient depletion (6).

Alopecia Areata and Scarring Alopecias

Alopecia areata (AA) is an autoimmune condition producing well-demarcated, smooth, circular patches of hair loss. It affects roughly 2% of the global population at some point in their lifetime (7). Scarring alopecias, such as lichen planopilaris and central centrifugal cicatricial alopecia (CCCA), permanently destroy follicles and require prompt specialist referral to slow progression.

When to See a Doctor About Hair Thinning

Most people delay seeking care, but early evaluation produces better outcomes for every treatable cause. You should schedule an appointment within two to four weeks if any of the following apply.

Red-Flag Signs That Need Prompt Attention

See a clinician promptly when hair thinning is accompanied by:

• Patchy or circular bald spots appearing within weeks
• Scalp pain, burning, tenderness, or itching that persists beyond a few days
• Visible scalp scaling, redness, or pustules (possible tinea capitis or folliculitis)
• Eyebrow, eyelash, or body hair loss alongside scalp thinning
• Shedding that began abruptly and exceeds roughly 200 to 300 hairs per day
• Associated symptoms of systemic disease: fatigue, weight change, palpitations, irregular periods, or new acne

The National Alopecia Areata Foundation notes that scarring alopecias in particular "require early, aggressive treatment to prevent permanent follicle destruction," making prompt dermatology referral a clinical priority (8).

The 3-Month Rule

Gradual, diffuse thinning without red flags can be observed for up to three months if a clear trigger (recent illness, delivery, surgery) is identified. Beyond three months without improvement, or at any time the shedding accelerates, a workup is appropriate. The British Association of Dermatologists' guidelines on chronic telogen effluvium specify that "investigations should be initiated when the condition has been present for longer than six months or when clinical assessment suggests a systemic cause" (9).

Hair Thinning at Younger Ages

Hair thinning in patients under 30 warrants earlier evaluation because it is more likely to signal an underlying medical condition (thyroid disease, PCOS, nutritional deficit) than in older adults where AGA predominates. A 2020 cross-sectional study in Skin Appendage Disorders found that 34% of women under 35 presenting with diffuse hair loss had a correctable systemic cause on laboratory workup (10).

How Hair Thinning Is Diagnosed

A systematic diagnostic approach prevents misdiagnosis, which is common: the clinical features of TE and early AGA overlap considerably in women.

History and Physical Examination

The clinician will assess onset, rate of progression, pattern of loss, shedding volume, family history, medications, recent illnesses, dietary changes, and hormonal events. Physical examination includes the pull test (grasping 40 to 60 hairs and pulling firmly; more than 6 hairs released indicates active shedding), dermoscopy of the scalp, and an assessment of hair shaft caliber.

A structured history alone correctly classifies approximately 65% of hair loss cases before any laboratory testing, according to a review in JAMA Dermatology (11).

Laboratory Workup

A standard first-pass panel typically includes:

• TSH (thyroid-stimulating hormone): screen for hypothyroidism and hyperthyroidism
• Serum ferritin: iron stores; a level below 30 ng/mL may drive TE independently of hemoglobin
• CBC with differential: anemia, infection, or inflammatory markers
• Free testosterone and DHEA-S: androgen excess in women
• Prolactin: hyperprolactinemia as a hormonal driver
• Vitamin D (25-OH): deficiency correlates with AA in observational data (12)
• ANA: if autoimmune etiology is suspected

Scalp Biopsy

When the diagnosis remains unclear after history, examination, and labs, a 4-mm punch biopsy of affected scalp provides histopathologic confirmation. Biopsy is particularly useful to distinguish scarring from non-scarring alopecias and to confirm AA. The American Academy of Dermatology recommends biopsy whenever a scarring alopecia is suspected, because treatment delay directly correlates with permanent follicle loss (13).

Treatments for Hair Thinning

Treatment selection depends entirely on the diagnosis. There is no universal hair-thinning remedy that works across all causes.

Topical and Oral Minoxidil

Minoxidil is the only FDA-approved topical treatment for androgenetic alopecia in both men (5% solution or foam) and women (2% and 5% solution). Its mechanism is not fully established but likely involves prolongation of the anagen phase and vasodilation of scalp microvasculature.

A 48-week randomized controlled trial published in the Journal of the American Academy of Dermatology (N=393) showed that 5% minoxidil foam produced a mean 18.6 increase in target area hair count versus baseline, compared to 3.9 in the placebo group (P<0.001) (14).

Low-dose oral minoxidil (0.25 mg, 5 mg daily) has gained traction as an off-label option. A 2021 retrospective study in JAAD (N=1,404 patients) found that 1 to 5 mg daily oral minoxidil produced a "good or excellent" response in 78.9% of patients with various hair loss diagnoses, with hypertrichosis as the most common side effect (15).

Finasteride and Dutasteride

Finasteride 1 mg daily inhibits type II 5-alpha-reductase, reducing scalp DHT by approximately 60 to 70%. Two key Phase III trials (combined N=1,553) showed that finasteride 1 mg produced statistically significant increases in hair count at 12 and 24 months versus placebo, with 83% of men showing no further progression at 2 years (16).

Finasteride is approved for men only. Women of childbearing potential must avoid it due to risk of fetal genitourinary abnormalities. Dutasteride 0.5 mg daily inhibits both type I and type II 5-alpha-reductase and is approved for AGA in several countries; a 2014 RCT in JAAD (N=917) showed dutasteride produced greater hair count increases than finasteride at 24 weeks (17).

Spironolactone for Women

Spironolactone 50 to 200 mg daily is used off-label in women with AGA or androgen-driven hair loss. Its anti-androgenic mechanism blocks DHT at the receptor level. A retrospective cohort study published in the Journal of the American Academy of Dermatology (N=80) found that 74% of women reported stabilization or improvement of hair loss after 12 months on spironolactone (18).

Serum potassium should be monitored, particularly in patients on ACE inhibitors or with renal insufficiency.

JAK Inhibitors for Alopecia Areata

Baricitinib (Olumiant) received FDA approval in June 2022 for severe alopecia areata, the first systemic treatment approved specifically for AA. In the BRAVE-AA1 trial (N=654), 38.8% of patients on baricitinib 4 mg achieved a SALT score of 20 or below (indicating at least 80% scalp coverage) at week 36, compared to 6.6% on placebo (19). Ritlecitinib (Litfulo) received FDA approval in June 2023 for patients aged 12 and older with severe AA.

Treating the Underlying Cause

For TE driven by iron deficiency, correcting ferritin to above 70 ng/mL is the primary intervention. For thyroid-driven hair loss, normalizing TSH with levothyroxine typically restores shedding to baseline within 6 to 9 months. For PCOS-related androgen excess, combined oral contraceptives or spironolactone address both the hormonal imbalance and the follicular effect.

The following framework summarizes the diagnostic-to-treatment pathway that the HealthRX clinical team applies in evaluating new hair thinning presentations:

| Pattern | First-Pass Labs | Likely Diagnosis | First-Line Treatment | |---|---|---|---| | Diffuse shedding, acute onset | TSH, ferritin, CBC | Telogen effluvium | Correct trigger; reassure | | Frontal/crown recession, gradual | Free testosterone, DHEA-S | Androgenetic alopecia | Minoxidil +/- finasteride | | Patchy smooth circles | ANA, thyroid panel | Alopecia areata | Intralesional steroids; baricitinib for severe AA | | Scalp scaling + itching | KOH prep, culture | Tinea capitis | Oral griseofulvin or terbinafine | | Diffuse + fatigue + cold intolerance | TSH, free T4 | Hypothyroidism | Levothyroxine |

Platelet-Rich Plasma and Other Procedures

Platelet-rich plasma (PRP) injections deliver concentrated growth factors directly to the scalp. A meta-analysis in Dermatologic Surgery (9 RCTs, N=223) found that PRP produced a statistically significant increase in hair density and hair count compared to controls (P<0.05), though heterogeneity of protocols limits definitive conclusions (20). Hair transplant surgery (follicular unit excision or FUE) is appropriate for stable, non-scarring AGA after medical therapy has been optimized for at least 12 months.

Medications That Cause Hair Thinning

Several commonly prescribed drugs list hair thinning as a recognized side effect. Beta-blockers (propranolol, metoprolol), anticoagulants (warfarin, heparin), lithium, valproate, retinoids (isotretinoin, acitretin), and chemotherapy agents are the most frequently implicated. Drug-induced TE typically appears 2 to 4 months after starting or increasing the offending agent (21).

GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy) have attracted attention for hair shedding. Post-marketing data and the SUSTAIN-6 trial adverse event reports suggest that the hair loss is consistent with TE secondary to rapid weight loss rather than a direct follicular drug effect. The shedding generally stabilizes as body weight plateaus (22).

What Happens If Hair Thinning Goes Untreated

For androgenetic alopecia, untreated progression is predictable and permanent at the follicular level. Once a follicle has fully miniaturized it cannot regenerate hair without surgical intervention. Five-year follow-up data from the original finasteride trials showed that men on placebo lost an average of 5.1% of scalp hair count per year, while men on finasteride maintained or gained hair (16).

Scarring alopecias cause irreversible destruction with each month of delayed treatment. Autoimmune-driven AA can spontaneously remit in up to 50% of limited-patch cases but carries a 10 to 15% risk of progression to total scalp alopecia (alopecia totalis) or total body hair loss (alopecia universalis) (7).

Treatable systemic causes (hypothyroidism, iron deficiency) produce complete or near-complete hair recovery when corrected early. Delay beyond 12 to 18 months may reduce the extent of recovery.